p53 in drug resistance in ovarian cancer.
Lavarino
C
C
Delia
D
D
Di Palma
S
S
Zunino
F
F
Pilotti
S
S
D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy / Q000235:genetics*; D004249:DNA Damage; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics*; D017239:Paclitaxel / Q000008:administration & dosage; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D012074:Remission Induction
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel